BackGreenLight Biosciences Overview

GreenLight Biosciences Long Term Debt

GreenLight Biosciences's long-term debt is $60M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$59.56M
151.46% YoYΔ $35.87M vs prior year quarter

Peer trimmed avg / median

Loading

GreenLight Biosciences Long Term Debt History

Loading

GreenLight Biosciences vs. peers: Long Term Debt Comparison

Loading

GreenLight Biosciences Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

GreenLight Biosciences (GRNA) FAQ

As of the most recent data (March 2023), GRNA shows a long-term debt of $60M. That compares with $24M in the prior-year period — up 151.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GRNA's long-term debt is now $60M (was $24M) — a 151.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether GreenLight Biosciences is outperforming or lagging.

Tracking GRNA's long-term debt over time shows whether GreenLight Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $60M That compares with $24M in the prior-year period — up 151.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has GreenLight Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $60M) with ownership activity and broader fundamentals.